

ValiRx PLC

10:58 30 Apr 2015

ValiRx eyes international partnerships

Cancer-focused life science company ValiRx (LON:VAL) has accepted an invitation to participate in a visit to the 2015 BIO International Convention in Philadelphia,

The Market Visit has been organised by the Mayor of London's Export Programme, in partnership with UK Trade & Investment (UKTI), to offer London's small-to-medium sized enterprises (SMEs) an opportunity to attend this major industry international event where they will get a chance to mingle with representatives of the world's leading pharmaceutical and biotechnology companies.

Last year's convention featured more than 1,800 exhibitors and 55 state, regional and country pavilions in an area of over 160,000 square feet. The convention was visited by attendees from leading biotech companies, top 25 pharma companies and more than 300 academic institutions, including research labs and government agencies, ValiRx reported.

Furthermore, according to the 2013 Campbell Alliance's "Deal Makers' Intentions" report, the majority of successful deals in the biopharma industry are a result of participating in these sorts of partnering events.

"I am delighted ValiRx has been invited to join an impressive British delegation of biotech businesses attending this major industry event," said Dr Satu Vainikka, chief executive officer of ValiRx.

"I look forward to the company building its profile on the international stage, particularly following our successful poster presentation at the recent American Association for Cancer Research (AACR) conference in Philadelphia and I look forward to ValiRx expanding its network of relationships to the benefit of our shareholders," he added.

Shares in ValiRx were up 2.4% in late morning trading.

Price: 7.5

Market Cap: £2.7 m

1 Year Share Price Graph



May 2019 November 2019 May 2020

Share Information

Code: VAL

Listing: AIM

52 week	High	Low
	68.4625	2.65

Sector: Pharma & Biotech

Website: www.valirx.com

Company Synopsis:

ValiRx PLC is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering. We focus on the novel treatments of cancers and associated Biomarkers. Our technologies and products however can also be applied to the other fields as well, such as neurology and inflammatory diseases.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).